Prague pharmaceutical company Zentiva announced a step forward in its sustainability strategy with official validation of its targets by the Science Based Targets initiative (SBTi).

By setting near-term and long-term net-zero GHG reduction targets in line with the SBTi, this commitment reinforces Zentiva’s dedication to sustainability and aligns with the company’s decarbonization roadmap and the European Union’s goal of becoming the first climate-neutral continent by 2050.

Unlike carbon neutrality claims that may rely on offsets, SBTi requires companies to prioritize deep emissions reductions of up to 90%, before addressing residual emissions through carbon removals.

Zentiva commits to reach net-zero GHG emissions across the value chain by 2050. The company also commits to reduce absolute Scope 1 and 2 GHG emissions 63% by 2034 from a 2021 base year and Scope 3 GHG emissions 63% by 2034 from a 2024 base year.

The company commits to reduce absolute Scope 1 and 2 GHG emissions 90% by 2050 from a 2021 base year and Scope 3 GHG emissions 90% by 2050 from a 2024 base year.

Zentiva’s sustainability efforts extend beyond decarbonization to include measurable reductions in energy use, water consumption and the amount of waste generated from its production, along with a focus on biodiversity restoration projects. 

“We are proud the SBTi has validated our climate targets,” said Ines Windisch, head of corporate affairs and sustainability, in a statement. “Europe is heating up and climate change is no longer a distant threat, but our present reality. Ambition alone won’t cool down the planet. We have to turn the ambition into action, and our strategy for decarbonization is the cornerstone of that. Thanks to the engagement of our team and our partners, we can make a meaningful impact across our operations and communities. We cannot fight climate change alone. At Zentiva, every small step counts, and we are proud of our achievements so far.”